40 completed, 24 unknown, 9 terminated, 6 withdrawn. 28 Phase 3, 27 Phase 2, 21 Not applicable, 8 Phase 1, 4 Early Phase 1.
Follow Riboflavin: new trials by email Literature Review of Riboflavin trials Research Report on Riboflavin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions Vitamin C, Vitamin B2, Astragalus Root dry extract etc - Bioavailability and Pharmacokinetics | Not applicable | Not yet recruiting | Sichuan Credit Pharmaceutical Co., Ltd. | 32 | 2026-06-01 | 2026-07-01 |
| Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light - Keratoconus, Corneal Ectasia | Phase 2 / Phase 3 | Recruiting | Price Vision Group | 500 | 2025-10-01 | 2026-09-25 |
| Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment - Keratoconus | Phase 3 | Completed | Epion Therapeutics | 398 | 2023-11-01 | 2026-06-25 |
| Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment - Keratoconus | Phase 3 | Completed | Epion Therapeutics | 396 | 2023-10-30 | 2026-06-25 |
| Cytoflavin in the Complex Rehabilitation of Stroke Patients Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Stroke | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 240 | 2023-06-30 | 2026-04-14 |
| Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes Riboflavin, Placebo - Muscle Soreness | Early Phase 1 | Completed | Steven Moore | 150 | 2023-06-23 | 2025-04-03 |
| Pack Cross Linking for Infectious Keratitis Riboflavin, Antibotice.g vigamox ED Antifungal e.g Dflucan, pack cross linking - Infectoius Keratitis | Not applicable | Unknown | Sohag University | 60 | 2023-06-15 | 2023-05-31 |
| Effect of Colon Delivered Vitamin B2 on Gut Microbiota and Related Health Biomarkers in Healthy Older Adults Riboflavin - Quality of Life | Not applicable | Completed | dsm-firmenich Switzerland AG | 348 | 2022-12-12 | 2026-11-10 |
| Intervention With Riboflavin to Improve Vascular Health and ENdothelial Functioning in Genetically at- Risk Adults Placebo, Riboflavin 1.6mg/d, Riboflavin 5mg/d - Blood Pressure, Hypertension | Not applicable | Unknown | University of Ulster | 120 | 2022-09-01 | 2022-08-09 |
| Cytoflavin in Combination With Reperfusion in Stroke Patients Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control - Acute Stroke | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 200 | 2022-04-10 | 2023-03-20 | |
| Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears - Keratitis, Corneal Ulcer | Phase 2 / Phase 3 | Unknown | Peschke GmbH | 488 | 2022-03-14 | 2022-10-28 |
| Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears - Keratitis, Corneal Ulcer | Phase 2 / Phase 3 | Unknown | Peschke GmbH | 468 | 2022-03-14 | 2022-10-28 |
| Riboflavin for Glutamate Reduction in Alcohol Withdrawal Riboflavin, Placebo - Alcohol Withdrawal, Nutrition Disorders | Phase 2 | Unknown | Oregon Health and Science University | 40 | 2021-12-01 | 2021-09-29 |
| Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL) Riboflavin - Keratoconus, Unstable | Early Phase 1 | Not yet recruiting | Kent Wellish MD | 600 | 2021-06-30 | 2021-05-25 |
| Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia Riboflavin - Keratoconus, Corneal Ectasia | Phase 3 | Unknown | Cornea and Laser Eye Institute | 160 | 2021-06-02 | 2023-01-04 |
| Iron and Vitamin Supplementation in Hip/Knee Surgery Iron plus folic acid, vitamin B2, B6, B12, C, and E - Orthopedic Disorder, Hip Arthropathy | Not applicable | Completed | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 60 | 2021-04-21 | 2023-05-06 |
| Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose Riboflavin - Keratoconus, Corneal Ectasia | Phase 3 | Unknown | Cornea and Laser Eye Institute | 170 | 2021-04-16 | 2023-01-04 |
| Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Diabetic Neuropathies | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 216 | 2020-11-25 | 2023-01-27 |
| International Trial of Efficacy of Cytoflavin in Head Trauma Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Head Trauma,Closed | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 166 | 2020-11-22 | 2025-04-18 |
| Head Yuanshi Dian Therapy in Burning Mouth Syndrome oryzanol + vitamin B2 (riboflavin) + vitamin E - Burning Mouth Syndrome, Oral Mucosa Disease | Early Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 290 | 2020-07-27 | 2021-07-19 |
Showing 20 of 83. Sign in to see all of them.
Keratoconus (28) · Dilatation, Pathologic (10) · Corneal Diseases (5) · Corneal Ulcer (4) · Brain Concussion (3) · HIV Infections (3) · Acidosis, Lactic (2) · Cognitive Dysfunction (2) · Hypertension (2) · Keratitis (2) · Stroke (2) · Abortion, Habitual (1) · Acquired Immunodeficiency Syndrome (1) · Alcoholism (1) · Anemia (1)
Cornea and Laser Eye Institute (5) · POLYSAN Scientific & Technological Pharmaceutical Company (5) · University of Ulster (4) · Cxlusa (3) · Price Vision Group (3) · Topcon Medical Systems, Inc. (3) · dsm-firmenich Switzerland AG (3) · Epion Therapeutics (2) · Joseph B. Ciolino, MD (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Peschke GmbH (2) · Stephen Trokel (2) · University of Missouri-Columbia (2) · University of Virginia (2) · Assistance Publique - Hôpitaux de Paris (1)
United States (44) · United Kingdom (6) · Russia (5) · Canada (3) · Ireland (3) · Austria (2) · Brazil (2) · China (1) · Egypt (1) · France (1) · Germany (1) · Greece (1) · India (1) · Iran (1) · Israel (1)
William Trattler, MD (3) · Bala Ambati (2) · Francis W Price, MD (2) · Michael Belin, MD (2) · Peter Hersh, MD (2) · Peter S Hersh, MD (2) · Stephen Trokel, MD (2) · Steven A Greenstein, MD (2) · Yvette Viscuso (2) · Aimee McRae-Clark, PharmD, BCPP (1) · Aleksandar Stojanovic, MD (1) · Alexander V Savello, Prof (1) · Alexey Shmonin, Prof (1) · Belquiz A Nassaralla, MD, PhD (1) · Bernard Cholley, MD, PhD (1)
PMID 32557558, PMID 18471635, PMID 15076242, PMID 16765803, PMID 16952090, PMID 18811118, PMID 20138607, PMID 20164744, PMID 22741619, PMID 23062001, PMID 23929075, PMID 24507091, PMID 25938990, PMID 26997458, PMID 27418639, PMID 27496105, PMID 27899371, PMID 28325070, PMID 28787507, PMID 29203068, PMID 32532654, PMID 33615992, PMID 33779986, PMID 35680173, PMID 35943883, PMID 37343287, PMID 41551305
2017 (1), P01NS044233 (1), P50DA009236 (1), R01DA025074 (1), R21AG050850 (1), U54NS065736 (1)